Matthew Hann, MD
Cardiovascular Disease · Keesler Afb, MSNPI 1275749541
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.8% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2023 at $10,259 and has fallen 72.7% since, to $2,796 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 696 payments — averaging $56.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$29K
- Abbott$907
- Boston Scientific$801
- Novartis$790
- Pfizer$755
- Merck$736
- plus $6K from 45 others
What the payments were for
- Consulting fees$6,22516%
- Speaking & faculty fees$13,50034%
- Travel & lodging$5,14813%
- Food & beverage$14,65237%
- Education$80%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$15,128
- SelectSecure$510
- Pounce Venous Thrombectomy System$341
- GlideWire$239
- Sublime 014 Rx PTA Balloon Dilatation Catheter$227
- Sublime Microcatheter, 018, 200cm, Straight$227
- Pounce Thrombectomy System$227
- Pounce Thrombectomy$227
- AlphaVac$157
- WATCHMAN Access System$142
- Diamondback Coronary$132
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$132
- Reveal LINQ$125
- Navicross$123
- Glidesheath$123
- GENERAL - STRUCTURAL HEART$122
- METACROSS OTW$116
- GLIDESHEATH SLENDER$116
How this compares
$39,609 in reported general payments places this provider in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 213 | $247,928 |
| EntrestoSacubitril/Valsartan | 99 | $119,852 |
| XareltoRivaroxaban | 42 | $48,600 |
| Repatha SureclickEvolocumab | 18 | $15,140 |
| FarxigaDapagliflozin Propanediol | 17 | $13,104 |
| MultaqDronedarone Hcl | 11 | $9,066 |
| JardianceEmpagliflozin | 11 | $8,228 |
| Metoprolol Succinate | 179 | $2,782 |
| ClopidogrelClopidogrel Bisulfate | 143 | $1,365 |
| Atorvastatin Calcium | 150 | $1,151 |
| Flecainide Acetate | 12 | $981 |
| Valsartan | 20 | $790 |
| Losartan Potassium | 103 | $708 |
| Rosuvastatin Calcium | 80 | $687 |
| Carvedilol | 118 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $755 | $247,928213 claims |
| NovartisEntresto | $790 | $119,85299 claims |
| Johnson & JohnsonXarelto | $575 | $48,60042 claims |
| AstraZenecaFarxiga | $155 | $13,10417 claims |
| Sanofi-aventis U.S. LLCMultaq | $48 | $9,06611 claims |
| Boehringer IngelheimJardiance | $378 | $8,22811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Keesler Afb
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
- Tahsin QarqishJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.